Latest close: a new 52-week lowSep 8, 2026what changed →
Is the price fair?
What IDXX's price assumes
Idexx Laboratories trades at 36.6× earnings against 33.6× for the median Diagnostics & Research name, more expensive than its own group.
36.6
Trailing P/E · Diagnostics & Research median 33.6 · 1.09× the median: the market pays up for this one
- Price / sales
- 10.1
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.8%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered +28% a year over the last three.
Details›
- Price / book2026-Q1
- 28.9
- EV / EBIT2026-Q1
- 32.1
- EV / sales2026-Q1
- 10.2
- Healthcare median P/E362 names
- 29.9
- Diagnostics & Research median P/E29 names
- 33.6
- Free cash flow, trailing twelve months
- $1.25B
- Market capitalisation
- $44.3B
- 3-year revenue growth
- +9.0%
- 3-year free cash flow growth
- +28%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $713.80 |
| Its own P/E history, median | $763.00 |
| Its own P/E history, upper quartile | $823.41 |
| 52-week range | $520.59 – $766.68 |
| Today | $520.59 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
The closest names by size in the same industry